BioCryst Pharmaceuticals (BCRX) financial statements
BioCryst Pharmaceuticals reported revenue of $875M in fiscal 2025, up 47.6% a year over 9 years.
Net income was $264M and the operating margin 39.0%, against -184.4% in 2016.
Free cash flow was $345M.
The diluted share count rose 197% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from BioCryst Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $26M | $25M | $21M | $49M | $18M | $157M | $271M | $331M | $451M | $875M |
| Cost of revenue | $2M | $1M | — | $4M | $2M | $7M | $6M | $4M | $12M | $19M |
| Gross profit | $24M | $24M | — | $45M | $16M | $150M | $264M | $327M | $438M | $856M |
| Research and development | $61M | $67M | $85M | $107M | $123M | $209M | $253M | $217M | $175M | $166M |
| Selling, general and admin | $11M | $14M | $30M | $37M | $68M | $119M | $159M | $214M | $266M | $349M |
| Operating income | -$49M | -$57M | -$94M | -$99M | -$175M | -$178M | -$148M | -$104M | -$3M | $341M |
| Interest expense | $6M | $9M | $9M | $12M | $15M | $59M | $99M | $108M | $99M | $79M |
| Pre-tax income | — | — | — | -$109M | -$183M | -$182M | -$244M | -$226M | -$87M | $267M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $2M | $3M | $310,000 | $2M | $4M |
| Net income | -$55M | -$66M | -$101M | -$109M | -$183M | -$184M | -$247M | -$227M | -$89M | $264M |
| EPS (diluted) | -$0.75 | -$0.78 | -$0.98 | -$940.00 | -$1.09 | -$1.03 | -$1.33 | -$1.18 | -$0.43 | $1.21 |
| Diluted shares | 74M | 84M | 103M | 116M | 167M | 179M | 186M | 192M | 207M | 219M |
| Gross margin | 91.3% | 95.5% | — | 92.4% | 91.3% | 95.4% | 97.6% | 98.6% | 97.3% | 97.8% |
| Operating margin | -184.4% | -227.9% | -456.2% | -203.7% | -981.1% | -113.1% | -54.8% | -31.3% | -0.6% | 39.0% |
| Net margin | -209.3% | -261.2% | -490.3% | -223.0% | -1026.4% | -117.1% | -91.2% | -68.4% | -19.7% | 30.2% |
Balance sheet
Fiscal years, from BioCryst Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $55M | $114M | $104M | $136M | $300M | $508M | $424M | $389M | $321M | $275M |
| Receivables | $9M | $6M | $4M | $22M | $9M | $29M | $51M | $57M | $79M | $107M |
| Inventory | $500,000 | — | $2M | $0 | $7M | $16M | $28M | $29M | $8M | $5M |
| Total current assets | $67M | $125M | $114M | $164M | $324M | $566M | $516M | $496M | $422M | $404M |
| Property, plant and equipment | $10M | $10M | $9M | $7M | $7M | $9M | $9M | $8M | $8M | $9M |
| Total assets | $90M | $178M | $147M | $175M | $335M | $588M | $550M | $517M | $490M | $514M |
| Total current liabilities | $54M | $75M | $69M | $92M | $106M | $104M | $106M | $150M | $160M | $196M |
| Long-term debt | — | — | — | $0 | $120M | $136M | $232M | $303M | $315M | $0 |
| Total liabilities | $88M | $94M | $98M | $137M | $354M | $695M | $845M | $972M | $966M | $633M |
| Shareholders' equity | $2M | $84M | $49M | $38M | -$19M | -$107M | -$295M | -$456M | -$476M | -$119M |
| Net debt | -$22M | -$50M | -$27M | -$114M | -$152M | -$368M | -$73M | $193M | $210M | -$90M |
Cash flow
Fiscal years, from BioCryst Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$53M | -$41M | -$93M | -$90M | -$135M | -$142M | -$162M | -$95M | -$52M | $347M |
| Capital spending | $5M | $328,000 | $366,000 | $343,000 | $514,000 | $2M | $1M | $2M | $1M | $2M |
| Free cash flow | -$59M | -$41M | -$93M | -$90M | -$136M | -$145M | -$163M | -$97M | -$53M | $345M |
| Stock-based compensation | $8M | $13M | $9M | $18M | $15M | $35M | $45M | $56M | $65M | $85M |
| Net borrowing | — | — | — | — | — | $0 | $73M | $60M | $0 | -$300M |
| Free cash flow margin | -222.8% | -164.7% | -450.0% | -184.1% | -761.4% | -92.0% | -60.3% | -29.4% | -11.8% | 39.4% |
Questions
What was BioCryst Pharmaceuticals's revenue in 2025?
$875M in fiscal 2025, from its 10-K filing.
How much free cash flow does BioCryst Pharmaceuticals generate?
$345M in fiscal 2025 (operating cash flow minus capital spending).
From BioCryst Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.